AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03136003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
Study NCT02706509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: patient will receive oral Tramadol 50 mg an hour before IUD insertion
Study NCT02706509 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal anesthesia
Description: patient will receive full explanation about the procedure for five minutes before IUD insertion
Study NCT02706509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jaydess
Description: Patient will go through an insertion of Jaydess intrauterine device.
Study NCT02706509 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Jaydess
Description: Patient will go through an insertion of Jaydess intrauterine device.
Study NCT04404738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPort® robot-assisted laparoscopic surgery
Description: In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
Study NCT04404738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci robot-assisted laparoscopic surgery
Description: In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
Study NCT02816060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual therapy with neural exercise will be applied on patients with neck pain
Study NCT02816060 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: manual therapy
Description: manual therapy with neural exercise will be applied on patients with neck pain
Study NCT05276245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Protocol of Nature Contact
Description: This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
Study NCT02225431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride infusion
Study NCT02225431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion
Study NCT02268877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Medicine Physician Ultrasound
Description: An ultrasound will be performed by an emergency medicine resident or attending physician
Study NCT02268877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound will be performed by a radiology department technician
Study NCT02268877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound will be performed by a radiology department technician
Study NCT03024190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stretching exercise
Description: 15- min stretching exercise for upper extremity twice daily
Study NCT03024190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: 15- min stretching exercise for upper extremity twice daily
Study NCT02626494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study NCT03024190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OT rehabilitation program
Description: regular rehabilitation program for 3 weeks
Study NCT03024190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT rehabilitation program
Description: regular rehabilitation program for 3 weeks
Study NCT02092311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Microscopic Varicocelectomy
Description: After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
Study NCT02092311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal and Subinguinal varicocelectomy
Description: Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
Study NCT02626494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study NCT01697956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP
Description: Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Study NCT01697956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03842228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study NCT03842228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT01681511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICET™ TIC Foley Catheter
Description: The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
Study NCT01681511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD® LUBRI-SIL® IC Foley Catheter
Description: The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03842228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03842228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT01496313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300mg vandetanib
Description: Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
Study NCT01496313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg vandetanib
Description: Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
Study NCT03513627 — intervention group
Intervention type: PROCEDURE
Intervention: Post-occlusive reactive hyperemia test (PORH test)
Description: Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
Study NCT03969927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Fidelity PDS
Description: The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills.
Study NCT03969927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Fidelity Fixed-Base Simulator
Description: This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
Study NCT04566432 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: observe the association of ctDNA with efficacy of treatment
Study NCT03124082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: continuous infusion intraop
Study NCT03124082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
Study NCT03124082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
Study NCT02233322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: All subjects will receive iron supplementation based on iron levels in the blood
Study NCT04542525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ PanOptix Toric Trifocal IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
Study NCT04542525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
Study NCT03124082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine 4 mcg/kg
Study NCT03993522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test
Description: Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
Study NCT00068302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: 3-6 subjects will be enrolled into each dose level
Study NCT03596684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrulline supplementation
Description: 2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
Study NCT03596684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplementation
Description: 2.5 g of the product in the morning and in the evening during 4 weeks.
Study NCT03596684 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: glucose tolerance test
Description: 2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
Study NCT02409966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadrant-wise scaling
Description: Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
Study NCT01524861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo tablet bis in die for 12 months
Study NCT01524861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
Study NCT01524861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-acetyl carnitine
Description: L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
Study NCT02409966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth 24-hour scaling
Description: Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
Study NCT05720936 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous stellate ganglion block (PSGB)
Description: Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach
Study NCT02136719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bimanual uterine compression
Description: bimanual uterine compression immediately after delivery of placenta for 5 minutes
Study NCT04420390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Low-dose radiotherapy
Study NCT03651011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
Study NCT03651011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated laser photocoagulation
Description: Navigated laser photocoagulation planned from flourscein angiography.
Study NCT02984228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Study NCT02984228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study NCT02984228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT03753867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
Study NCT03049189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-edotreotide PRRT
Description: PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
Study NCT03049189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
Study NCT03049189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino-Acid Solution
Description: The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
Study NCT01329991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
Study NCT01329991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PLX5622
Study NCT01917214 — intervention group
Intervention type: OTHER
Intervention: Sutent: Observational Study
Description: Sutent oral therapy
Study NCT04359147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study NCT04359147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study NCT05018065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
Description: sexual dysfunction assesment
Study NCT02843035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat (GZ402671)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT02843035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiglucerase
Description: Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous
Study NCT00130026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 500 mg IV
Study NCT04553627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZELTIQ thermoelectric device
Description: This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
Study NCT02182362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Study NCT03432871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.